Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8.0 billion increased 5.3% as reported and 5.0% organic GAAP diluted earnings per share (... Read more
In an exclusive interview with BioPharma BoardRoom, Isabella Muñoz, Executive Director of Invest In Bogota, shares insights into how Bogota has positioned itself as a thriving hub for the biopharmaceutical industry. From strategic advantages t... Read more
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Imp... Read more
Novo Nordisk announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases. The i... Read more
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering... Read more
Perpetual Medicines announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery. The financing round was led by Chengwei Capital. The company also anno... Read more
Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million Biologics Testing Center opened in 2022 Enhances BioReliance® testing services portfolio in the Chinese ... Read more
Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremophiles. The acquisition provides Hovione with new high-performance func... Read more
© 2023 Biopharma Boardroom. All Rights Reserved.
